MRI MARKERS TO UNDERSTAND PROGRESSION MECHANISMS

Similar documents
Neuroplasticity: functional MRI techniques M.A. Rocca

MRI in ALS. Federica Agosta, MD, PhD

Neuroimaging and Other Biomarkers. MRI for Diagnosis, Prognosis and Treatment Decisions in MS

MRI in MS: the radiologist perspective

Review Article Gray Matter Pathology in MS: Neuroimaging and Clinical Correlations

MRI in MS. MRI in multiple sclerosis. MS T2 Lesions: Pathology. Brain lesions Morphology Matters. Sagittal FLAIR Morphology Matters

Published November 11, 2011 as /ajnr.A2864

ORIGINAL CONTRIBUTION. Magnetization Transfer Magnetic Resonance Imaging and Clinical Changes in Patients With Relapsing-Remitting Multiple Sclerosis

Progressive Multiple Sclerosis

Spinal cord MR imaging in Multiple Sclerosis

Primary Progressive MS. Predicting Progression. Alan J Thompson Director, UCL Institute of Neurology Queen Square

Clinical and research application of MRI in diagnosis and monitoring of multiple sclerosis

Clinical and research application of MRI in diagnosis and monitoring of multiple sclerosis

ECTRIMS-MAGNIMS MAGNETIC RESONANCE IMAGING IN MULTIPLE SCLEROSIS FELLOWS Awardees

3rd Nordic MS Symposium. Understanding progressive MS

ECTRIMS-MAGNIMS MAGNETIC RESONANCE IMAGING IN MULTIPLE SCLEROSIS FELLOWS Awardees

MRI in Multiple Sclerosis Features of Cerebral Atrophy with special focus on Multiple Sclerosis. E.W. Radue K. Bendfeldt Till Sprenger

Neurophysiology in diagnosis and monitoring of MS

Clinical Correlations of Brain Lesion Distribution in Multiple Sclerosis

MAGNIMS MRI in monitoring disease activity and progression

ORIGINAL CONTRIBUTION. Axonal Injury and Overall Tissue Loss Are Not Related in Primary Progressive Multiple Sclerosis

In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study

Periventricular T2-hyperintense lesions: does the number matter in CIS?

1 MS Lesions in T2-Weighted Images

The Effect of Glatiramer Acetate on. Spinal Cord Volume in Relapsing#Remitting Multiple Sclerosis.

Visualisation of cortical MS lesions with MRI need not be further improved: Yes

MEDIA BACKGROUNDER. Multiple Sclerosis: A serious and unpredictable neurological disease

Neurology and Neurometabolic Unit Department of Neurological and Behavioral Sciences University of Siena Siena, Italy

MRI and differential diagnosis in patients suspected of having MS

Evidence from bone marrow transplantation

Massimo Filippi * 1. Introduction

Magnetization-Transfer Histogram Analysis of the Cervical Cord in Patients with Multiple Sclerosis

MRI in Differential Diagnosis. CMSC, June 2, Jill Conway, MD, MA, MSCE

Patologie infiammatorie encefaliche e midollari

Innovazione e personalizzazione nella terapia della SM. Rocco Totaro Centro per la Diagnosi e Cura delle Malattie Demielinizzanti L Aquila

Quantification of Brain Damage in Cerebrotendinous Xanthomatosis with Magnetization Transfer MR Imaging

ORIGINAL CONTRIBUTION. Cortical Lesions and Atrophy Associated With Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis

Multiple sclerosis is a chronic autoimmune inflammatory disease

Top 10 Research Findings of 2016

Relevance of Hypointense Lesions on Fast Fluid- Attenuated Inversion Recovery MR Images as a Marker of Disease Severity in Cases of Multiple Sclerosis

Gray matter networks and cognitive impairment in multiple sclerosis

Magnetic Resonance Imaging and Spectroscopy: Insights into the Pathology and Pathophysiology of Multiple Sclerosis.

MR imaging is a vital tool enabling clinicians to diagnose,

Cognitive Impairment and Diffusion Tensor Imaging of the Normal Appearing White Matter in Multiple Sclerosis Patients

T1- vs. T2-based MRI measures of spinal cord volume in healthy subjects and patients with multiple sclerosis

Hot Topics Multiple Sclerosis. Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018

Review Article Gray Matters in Multiple Sclerosis: Cognitive Impairment and Structural MRI

Cognitive Rehabilitation in Multiple Sclerosis: Its About Time!

Causes, effects and connectivity changes in MS-related cognitive decline

Use of MRI Technology in Determining Prognosis and Tracking Therapeutic Benefit in Multiple Sclerosis

Overview. Charcot (1868) A Behavioral and Neuroimaging Analysis of Cognitive Rehabilitation in Multiple Sclerosis. Multiple Sclerosis.

A Behavioral and Neuroimaging Analysis of Cognitive Rehabilitation in Multiple Sclerosis. John DeLuca, Ph.D. Senior Vice President for Research

MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients

Earliest MS: What Do We Know? RMMSC Education Summit May 12,2018. John R. Corboy, MD

Epidemiology, Diagnosis, Natural History & Clinical Course

12-13 February Milan, Italy

Topics in Neuroscience

Life Long Brain Health and DMT Comparative Effectiveness

MRI diagnostic criteria for multiple sclerosis: an update

T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis

Novartis real-world data at AAN confirms benefit of Gilenya on four key measures of disease activity in relapsing MS

Longitudinal changes in diffusion tensor based quantitative MRI in multiple sclerosis

Long-Term Changes of Magnetization Transfer Derived Measures from Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis

MR imaging has revolutionized the diagnosis and follow-up

NEW DIAGNOSTIC CRITERIA FOR MULTIPLE SCLEROSIS

Regional Cervical Cord Atrophy and Disability in Multiple Sclerosis: A Voxel-based Analysis 1

Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets

Corpus callosum index and long-term disability in multiple sclerosis patients

Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Neuromyelitis Optica in Singapore

1996 vs 2013 MS Phenotype Descriptions of Progressive Disease

Carolyn Taylor, M.D. Swedish Neuroscience Center

ORIGINAL CONTRIBUTION. Normal-Appearing Brain T1 Relaxation Time Predicts Disability in Early Primary Progressive Multiple Sclerosis

Helene Veenstra. Original publication available at: /ane Copyright: Wiley (12 months)

Novità diagnostiche nella Sclerosi Multipla

EAN Amsterdam June 23-27, 2017

Association of asymptomatic spinal cord lesions and atrophy with disability. 5 years after a clinically isolated syndrome

Evaluation cervical cord changes in the patients with MS and their comparison with vasculitis patients.

Conclusions: In this postmortem verification study, we have shown that 3D DIR is highly pathologically

Supplementary Online Content

Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis 1

Understanding cognitive decline in Multiple Sclerosis

Complementary roles of grey matter MTR and T2 lesions in predicting progression in early PPMS

Magnetization Transfer and Diffusion Tensor MR Imaging of Acute Disseminated Encephalomyelitis

Fingolimod for the treatment of Relapsing-Remitting Multiple Sclerosis

Structural lesion analysis: applications

Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes

Funding: NIDCF UL1 DE019583, NIA RL1 AG032119, NINDS RL1 NS062412, NIDA TL1 DA

Assessment and optimisation of MRI measures of atrophy as potential markers of disease progression in multiple sclerosis

Pediatric acute demyelinating encephalomyelitis in Denmark: a nationwide population-based study

Primary progressive multiple sclerosis: a 5-year clinical and MR study

Quantitative Neuroimaging- Gray and white matter Alteration in Multiple Sclerosis. Lior Or-Bach Instructors: Prof. Anat Achiron Dr.

CSF β-amyloid predicts prognosis in patients with multiple sclerosis

Multiple Sclerosis Journal

MAGNETIC RESONANCE IMAGING MARKERS OF LONG TERM DISABILITY IN RELAPSE-ONSET MULTIPLE SCLEROSIS PATIENTS. Leonora Kaloçi Fisniku, MBBS, MRCP(UK)

Glatiramer acetate recovers microscopic tissue damage in patients with multiple sclerosis. A case control diffusion imaging study

Progress in the field

MULTIPLE SCLEROSIS IN Managing the complexity of multiple sclerosis. Olga Ciccarelli and Alan Thompson

MS Academia: Multiple sclerosis advanced course

Early Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods. Christos Davatzikos, Ph.D.

Idiopathic Inflammatory Demyelinating Diseases of the Brainstem

Transcription:

MRI MARKERS TO UNDERSTAND PROGRESSION MECHANISMS Maria A. Rocca Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

Outline of presentation WM lesions: brain, spinal cord Atrophy WM damage: extent, topography GM damage: cortical lesions, diffuse and regional damage Spinal cord damage CNS reorganization (brain, spinal cord) Conclusions

Khaleeli et al., Mult Scler 2010 Tubridy et al., Neurology 1998 MRI & Progressive MS Brain WM lesions / Enhancement PPMS SPMS 45 PPMS with brain and spinal cord MRI for 5 years 15 (33%) had enhancing lesion at baseline 12 (26%) had enhancing lesion at 5 year 26 (58%) had 1 enhancing lesion during the study 19 (42%) had no enhancing lesion during the study 60 SPMS with monthly brain MRI for 4 months 32 (53%) had enhancing lesions at baseline 42 (70%) displayed one or more new enhancing lesions at follow-up 14 (23%) showed no enhancing lesions either at baseline or follow-up

Mesaros et al., J Neurol 2008 RRMS MRI & Progressive MS Brain WM lesions / Prognosis T2 lesions Similar slope of the relationship between baseline T2LV and EDSS in RRMS and SPMS Median yearly T2LV change: 0.27 ml in RRMS, and 0.30 ml in SPMS (p=0.59) 101 PPMS followed up for 10 yrs Khaleeli et al., Ann Neurol 2008 Sormani et al., Neurology 2009

Bodini et al., JNNP 2011 Ceccarelli et al., NeuroImage 2008 Di Perri et al., Arch Neurol 2008 MRI & Progressive MS Brain WM lesions / Distribution T2 lesion maps PPMS T1 lesion maps CIS RR SP PP PP vs RR: 29 vs 19% peak probability Higher T1 lesion occurrence in the CC, CST and other tracts adjacent to the lateral ventricles in SPMS vs RRMS Filli et al., MSJ 2012 T2 lesion location vs disability worsening

Spinal cord / T2 lesions Rovaris et al., Brain 2001 Controls 5.0 4.0 3.0 2.0 1.0 0.0 Number of cord lesions SPMS 6.0 5.0 4.0 3.0 2.0 1.0 0.0 PPMS Number of damaged cord segments 90.0 p = 0.03 Multiple hyperintense lesions in the spinal cord Rovaris et al., Brain 2001 60.0 30.0 0.0 Cord area [mm 2 ]

Outline of presentation WM lesions: brain, spinal cord Atrophy WM damage: extent, topography GM damage: cortical lesions, diffuse and regional damage Spinal cord damage CNS reorganization (brain, spinal cord) Conclusions

Ventricular volume change 21 CIS, 30 early relapse-onset, 41 RRMS, 23 SPMS MRI & Progressive MS Atrophy 1 y FU: 963 untreated MS patients p=0.001 p=0.001 n.s. p=0.003 p = 0.003 CIS MS RRMS SPMS (<1 year) Dalton et al., Neurology 2006 De Stefano et al., Neurology 2010

NWMV ** p<0.001 * p<0.01 MRI & Progressive MS Atrophy NGMV ** p<0.001 * p<0.01 GM atrophy rates: CIS RRMS and RRMS stable > HC (p=0.05) RRMS SPMS and SPMS > HC (p= 0.005) GM atrophy explains physical disability and cognitive impairment better than WM volume WM atrophy rates similar in all disease groups Fisher et al., Ann Neurol 2008 Roosendaal et al., MSJ 2011

Outline of presentation WM lesions: brain, spinal cord Atrophy WM damage: extent, topography GM damage: cortical lesions, diffuse and regional damage Spinal cord damage CNS reorganization (brain, spinal cord) Conclusions

FA MD MRI & Progressive MS NAWM damage RRMS BMS SPMS PPMS p=0.003 - p=0.004 p=0.01 Pulizzi et al., Arch Neurol 2007 CIS vs HC PPMS vs HC RRMS vs BMS SPMS vs RRMS SPMS vs PPMS 8 6 4 2 t value t value 5 4 3 2 1 t value t value Preziosa et al., Radiology 2011 Tortorella et al., Neurology 2000

Outline of presentation WM lesions: brain, spinal cord Atrophy WM damage: extent, topography GM damage: cortical lesions, diffuse and regional damage Spinal cord damage CNS reorganization (brain, spinal cord) Conclusions

GM damage / Cortical lesions Extensive subpial demyelination of the cerebellum in a PPMS case Focal demyelinated plaques in WM Cortical demyelination Demyelinated plaques in deep GM Kutzelnigg et al., Brain 2005

Calabrese et al., Neurology 2010 Geurts et al., Radiology 2005 Multi-slab 3D DIR MRI & PROGRESSIVE MS GM damage / Cortical lesions T2*-w / 7 T vs. SE = +538%; vs. FLAIR = +152% RRMS PPMS Cohen-Adad et al., NeuroImage 2011 DIR and disease evolution 48 PPMS patients followed up for 2 years Baseline CL volume: B: -0.525, p <0.001 Baseline T2-WM-LV: B: -0.448, p <0.001 Calabrese et al., Neurology 2009

GM damage / Cortical lesions Filippi et al., MSJ 2012 107 relapse-onset MS patients, 3-year FU Baseline CL volume: entire group: B=0.511; p<0.001 RRMS: B=0.512; p<0.001 SPMS: B=0.495; p<0.001 Calabrese et al., Ann Neurol 2010 334 relapse-onset MS patients, 5 years FU Age: OR 1.2, p =0.001 Baseline CL volume: OR 1.7, p <0.001 Baseline cerebellar cortical volume: OR 0.2, p <0.001 Calabrese et al., Ann Neurol 2013 Power to discriminate SPMS from BMS FA MD

Diffuse GM damage 241 relapse-onset MS patients followed up for 9 years Baseline GMF: OR 0.79 (CI 0.7 0.9) Baseline EDSS: OR 2.88 (CI 1.9 4.36) Lavorgna et al., MSJ 2013 73 relapse-onset MS patients followed up for 13 years Baseline GMF: OR 0.79, p=0.01 C index: 69% Cognitive deterioration at 13 year FU: Baseline average GM MTR (OR=0.87, p=0.03) Baseline disease duration (OR=1.50, p=0.08) C-index: 97% Filippi et al., Neurology 2013 Evolution to SPMS at 13 year FU: Baseline T2 LV (OR=1.13, p=0.005) Baseline GMF (OR=0.71, p=0.04) C-index: 84%

Regional GM damage Selective GM loss SPMS vs RRMS SPMS vs PPMS Ceccarelli et al., NeuroImage 2008

Outline of presentation WM lesions: brain, spinal cord Atrophy WM damage: extent, topography GM damage: cortical lesions, diffuse and regional damage Spinal cord damage CNS reorganization (brain, spinal cord) Conclusions

Rocca et al., Neurology 2011 CSAn MRI & Progressive MS Spinal cord / Atrophy C CSAn vs EDSS: r=-0.49, p<0.0001 EDSS Differential effect among disease clinical phenotypes (p<0.001): no association in CIS and BMS patients association in RRMS (r=-0.30), SPMS (r=-0.34) and PPMS patients (r=-0.27)

Rocca et al., JNNP 2013 PPMS vs HC MRI & Progressive MS Spinal cord damage BMS vs RRMS SPMS vs RRMS SPMS vs BMS SPMS vs PPMS P A L R P A L R P A L R P A L R P A L R CIS RRMS BMS PPMS SPMS T2 lesion probability

Spinal cord / Diffuse damage Normalized pixel count Average MD [x10-3 mm 2 s -1 ] (SD) Mean FA (SD) Controls 1.203 (0.09) 0.42 (0.04) PPMS 1.280 (0.10) 0.38 (0.05) p 0.024 0.007 70 60 50 40 30 20 10 0 Controls SPMS PPMS 0 10 20 30 40 50 60 70 80 MTR [%] Agosta et al., Neurology 2005 Composite MR model vs EDSS: Cord area + cord MTR peak height (r=0.21, p=0.04) Rovaris et al., Brain 2001

Spinal cord damage Crosssectional area RRMS SPMS PPMS Overall MD FA -10% -5% 0 +5% +10% +15% +20% UCCA, T1LV, diffuse abnormalities and number of involved segments were significant explanatory factors for clinical disability (R 2 = 0.564) Lukas et al., Radiology 2013 Baseline cross-sectional area and FA vs EDSS at follow-up: r = -0.40; p = 0.01 Agosta et al., Brain 2007

Outline of presentation WM lesions: brain, spinal cord Atrophy WM damage: extent, topography GM damage: cortical lesions, diffuse and regional damage Spinal cord damage CNS reorganization (brain, spinal cord) Conclusions

CNS reorganization / Brain CIS vs non-disabled RRMS SMC Mildly disabled RRMS vs SPMS SII SPMS vs mildly disabled RRMS Precuneus, IPL, MFG Non-disabled vs mildly disabled RRMS Precuneus, CMA, MFG SMC, SMA Thalamus MFG, IPL Rocca et al., Lancet Neurol 2005

CNS reorganization / Brain PPMS SPMS (reduced activations) STG L SMA BMS MFG L putamen Insula R cerebellum L SMC vs T2 lesion volume: r = 0.63, p < 0.001 Rocca et al., Neurology 2010 Filippi et al., NeuroImage 2002 Rocca et al., Neurology 2010

Rocca et al., Neurology 2010 MRI & Progressive MS CNS reorganization / Brain DMN fluctuations in progressive MS patients HC PPMS SPMS Correlations between DMN fluctuations and: PASAT (r=0.42, p<0.001) CC FA and JD (r ranging from 0.54 to 0.87, p<0.001) Cingulum FA (r=0.83, p<0.001)

CNS reorganization / Brain HC CP CI L SFG ACC ACC MCC Thal Precun MTG Put Cereb ITG (cr I) Cereb (cr II) Caud MCC Thal MTG OFC Cereb Sup TP ITG (cr I) Cereb (cr II) Sup TP MCC R ACC OFC Ling ACC ITG MTG Cereb (cr I) OFC Cereb (IV-V) Cereb (cr II) MCC MTG Cereb ITG (cr I) Cereb (cr II) MCC Thal ACC MTG Pall OFC ITG Cereb (cr I) Cereb (VIII) Put MCC ITG MTG Cereb (cr I) HCs RRMS BMS SPMS L SFG MCC Precun Put Thal ACC MTG Cer-crus-I ITG MCC Cer-crus-II MTG ACC Cer-crus-I SupTP ITG Cer-crus-II BMS MCC Thal MTG Cer-lobule-IV-V SupTP Cer-crus-I ITG Cer- Cer-lobule-VIII crus-ii Thal MTG SupTP Ling Cer-lobule-IV-V PHG ITG Cer-crus-I Cer-crus-II R ACC OFC ACC OFC MCC ITG MCC Put Pall MCC MTG Cer-crus-I Cer-crus-II MTG ITG Cer-crus-I ACC Thal MTG Ling Pall OFC Cer-crus-I ITG Cer-crus-II Cer-lobule-VIII ACC Put Thal MTG OFC Ling Pall ITG Cer- PHG crus-i Cerlobule-VI

Task-related average signal change [%] Cord average signal change (%) MRI & Progressive MS CNS reorganization / Spinal cord Controls SPMS PPMS Tactile stimulation of the palm of the R hand 5.0 4.5 4.0 3.5 2.7 % 0.7 % p=0.05 vs controls 3. 3 % 1.1 % p=0.02 vs controls 3.9 % 1.3 % Progressive MS vs controls: p=0.003 SPMS vs PPMS: p=0.05 Valsasina et al., Hum Brain Mapp 2011 3.0 2.5 Cord fmri vs fatigue 2.0 1.5 1.0 0.5 0.0 Controls RRMS SPMS Valsasina et al., JNNP 2010 Rocca et al., Mult Scler 2012

Outline of presentation T2 lesions: brain, spinal cord Atrophy WM damage: extent, topography GM damage: cortical lesions, diffuse and regional damage Spinal cord damage CNS reorganization (brain, spinal cord) Conclusions

Conclusions Modality Potential clinical value Feasibility Gd+ lesions Focal lesions Whole-brain atrophy NAWM damage GM damage Spinal cord damage Functional changes - + ++ ++ +++ +++ ++ +++ +++ +++ ++ ++ ++ +

Severity MRI in SPMS Theoretical background T2 lesions Functional changes Atrophy NAWM damage GM damage Cord damage Gd+ lesions RIS CIS RRMS SPMS/PPMS Time

DIVISION OF NEUROSCIENCE INSTITUTE OF EXPERIMENTAL NEUROLOGY Neuroimaging Research Unit & WM diseases group Director: M. Filippi Scientific coordinator: M.A. Rocca Department of Neurology G. Comi, B. Colombo, M. Comola, F. Esposito, V. Martinelli, F. Martinelli Boneschi, L. Moiola, G. Pavan, M. Rodegher Physicians: M. Absinta A. Bisecco G. Boffa S. Cirillo E. De Meo G. Longoni F. Mele R. Messina M.E. Morelli L. Parisi P. Preziosa G. Riccitelli Department of Neuroradiology A. Falini Gallarate Hospital, MS Centre A. Ghezzi Physicists: Technicians: MAGNIMS M. Copetti E. Pagani P. Valsasina L. Dall Occhio A. Meani P. Misci M. Petrolini S. Sala M. Sibilia R. Vuotto University of Belgrade V.S. Kostic, J. Drulovic, S. Mesaros